Table 2 Clinical characteristics of the transplanted patients.
From: Any modality of renal replacement therapy can be a treatment option for Joubert syndrome
Patient no | Age at transplant | Donor type of transplant | ABO compatibility | Immunosuppressive regimen | Period of observation after transplant (mo) | Rejection | Infection* | eGFR at the latest follow up (ml/min/1.73 m2) |
|---|---|---|---|---|---|---|---|---|
1 (1st) | 12.0 | DD | Compatible | Tac, MMF, mPSL, basiliximab | 2 days | No | None | Graft loss |
1 (2nd) | 22.3 | DD | Compatible | Tac, MMF, mPSL, basiliximab | 32.9 | No | None | 49.0 |
2a | 17.2 | DD | Compatible | Tac, MMF, mPSL, basiliximab | 17.1 | No | None | 107.7 |
3 | 11.5 | DD | Compatible | Tac, MMF, mPSL, basiliximab | 8.2 | No | CMV disease | 61.7 |
4 | 13.8 | DD | Compatible | Tac, MMF, mPSL, basiliximab | 134.2 | No | CMV infection | 83.0 |
5 | 11.3 | LD** | Compatible | Tac, MMF, mPSL, basiliximab | 10.2 | No | CMV infection | 89.5 |
7 | 6.8 | LD** | Compatible | CsA, MMF, mPSL, basiliximab | 18.2 | Yes | UTI CMV infection Adenovirus nephritis | 98.8 |
8 | 11.3 | LD** | Compatible | CsA, MMF, mPSL, basiliximab | 76.2 | No | None | 73.2 |
9 | 15.3 | LD** | Compatible | Tac, MMF, mPSL, basiliximab | 43.5 | No | None | 41.4 |
